Background: Proton pump inhibitors (PPIs) are the most potent antacids used in clinical practice with greater safety and efficacy. Limited data are available on the usage of PPIs in Indian health-care settings. Our aim was to understand the usage pattern and potential drug interactions with concurrently administered medications employing a single-day cross-sectional study design. Methods: A prospective observational cross-sectional study conducted on a single day, at two tertiary care teaching hospitals in South India. Inpatients of above 18 years of age were included. Case profiles were reviewed and data were collected in predesigned forms and analyzed. Drug interactions were identified using Micromedex and Medscape drug-interaction databases. Results: A total of 797 case profiles screened from both the centers; 714 were prescribed with PPIs. In intensive care units (ICUs), the use of PPIs was highest with 95% of cases getting these drugs. A PPI was seen in about 93% of patients, who had more than or equal to 4 drugs in their prescriptions. Pantoprazole was the mostly prescribed PPI in around 90% of the cases. Around 33% of the PPIs usage was through IV (intravenous) route, and 75% of that use was seen in wards. Around 134 drug interactions were identified, of which 10 were of major severity. Conclusions: Around 90% of inpatients were prescribed with PPIs. Pantoprazole is the most commonly prescribed PPI (90%). The IV administration was seen more in wards than ICUs, and 10 major drug interactions were observed in this single-day study. Careful monitoring is needed to avoid serious drug interactions involving PPIs, and training programs should sensitize the clinicians on the evidence-based use of PPIs.
BambergPCaswellCMFrameMHLamSKWongEC.A meta-analysis comparing the efficacy of omeprazole with H2-receptor antagonists for acute treatment of duodenal ulcer in Asian patients. J Gastroenterol Hepatol. 1992;7(6):577-585.
ScarpignatoCGattaLZulloABlandizziC.Effective and safe proton pump inhibitor therapy in acid-related diseases—a position paper addressing benefits and potential harms of acid suppression. BMC Med. 2016;14(1):179.
4.
PasinaLNobiliATettamantiM, et al. Prevalence and appropriateness of drug prescriptions for peptic ulcer and gastro-esophageal reflux disease in a cohort of hospitalized elderly. Eur J Intern Med. 2011;22(2):205-210.
5.
AhrensDChenotJFBehrensGGrimmsmannTKochenMM.Appropriateness of treatment recommendations for PPI in hospital discharge letters. Eur J Clin Pharmacol. 2010;66(12):1265-1271.
6.
KatzMH.Failing the acid test: benefits of proton pump inhibitors may not justify the risks for many users. Arch Intern Med. 2010;170(9):747-748.
AliTRobertsDNTierneyWM.Long-term safety concerns with proton pump inhibitors. Am J Med. 2009;122(10):896-903.
9.
HeidelbaughJJKimAHChangRWalkerPC.Overutilization of proton-pump inhibitors: what the clinician needs to know. Therap Adv Gastroenterol. 2012;5(4):219-232.
10.
Peyro Saint PaulLMartinJBuonM, et al. New frequent adverse reaction of PPI in older adults: mild hyponatremia. Therapie. 2014;69(2):157-162.
11.
MeyerUA.Interaction of proton pump inhibitors with cytochromes P450: consequences for drug interactions. Yale J Biol Med. 1996;69(3):203-209.
12.
StocklKMLeLZakharyanA, et al. Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor. Arch Intern Med. 2010;170(8):704-710.
13.
Mat SaadAZCollinsNLoboMMO’ConnorHJ.Proton pump inhibitors: a survey of prescribing in an Irish general hospital. Int J Clin Pract. 2005;59(1):31-34.
14.
ZinkDAPohlmanMBarnesMCannonME.Long-term use of acid suppression started inappropriately during hospitalization. Aliment Pharmacol Ther. 2005;21(10):1203-1209.
15.
HunginAPRubinGPO’FlanaganH.Long-term prescribing of proton pump inhibitors in general practice. Br J Gen Pract. 1999;49(443):451-453.
16.
SetiaMS.Methodology Series Module 3: cross-sectional studies. Indian J Dermatol. 2016;61(3):261-264.
17.
ChuriSJoganiA.Prospective assessment of prescribing pattern of intravenous proton pump inhibitors in an Indian tertiary-care teaching hospital. Indian J Pharm Pract. 2014;7(4):2-7.
18.
Machado-AlbaJFernándezACastrillónJD, et al. Prescribing patterns and economic costs of proton pump inhibitors in Colombia. Colomb Med. 2013;44(1):13-18.
19.
VoukelatouPVrettosIEmmanouilidouG, et al. Predictors of inappropriate proton pump inhibitors use in elderly patients. Curr Gerontol Geriatr Res. 2019;2019:7591045.
20.
PatilRAithalSHooliTVHVV. Drug utilisation study of proton pumps inhibitors in inpatients of a tertiary care hospital: a cross-sectional study. Natl J Integr Res Med. 2015;6(5):62-65.
21.
ShahsavaniNKoneriDRRRamaiahBThomasSM.Research article assessment of prescribing pattern of proton pump inhibitor and histamine 2 receptor antagonist. J Innov Pharm Biol Sci. 2016;3(3):13-22.
22.
KellyOBDillaneCPatchettSEHarewoodGCMurrayFE.The inappropriate prescription of oral proton pump inhibitors in the hospital setting: a prospective cross-sectional study. Dig Dis Sci. 2015;60(8):2280-2286.
23.
Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management. NICE, UK: Clinical Guidelines No. 184. http://www.NICE.org.uk/. Published 2014. Accessed August 19, 2019.
24.
SavarinoVMarioFDScarpignatoC.Proton pump inhibitors in GORD: an overview of their pharmacology, efficacy and safety. Pharmacol Res. 2009;59(3):135-153.
25.
NasserSCNassifJGDimassiHI.Clinical and cost impact of intravenous proton pump inhibitor use in non-ICU patients. World J Gastroenterol. 2010;16(8):982-986.
26.
NikfarSAbdollahiMMorettiMEMageeLAKorenG.Use of proton pump inhibitors during pregnancy and rates of major malformations: a metaanalysis. Dig Dis Sci. 2002;47(7):1526-1529.
27.
LalkinALoebsteinRAddisA, et al. The safety of omeprazole during pregnancy: a multicenter prospective controlled study. Am J Obstet Gynecol. 1998;179(3):727-730.
28.
HoPMMaddoxTMWangL, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009;301(9):937-944.
29.
BezabehSMackeyACKluetzPJapparDKorvickJ.Accumulating evidence for a drug-drug interaction between methotrexate and proton pump inhibitors. Oncologist. 2012;17(4):550-554.
30.
AnsariJ.Drug interaction and pharmacist. J Young Pharm. 2010;2(3):326-331.
31.
KheshtiRAalipourMNamaziS.A comparison of five common drug-drug interaction software programs regarding accuracy and comprehensiveness. J Res Pharm Pract. 2016;5(4):257-263.
